Details of Disease

General Information of Disease (ID: DIS6N9RZ)

Disease Name Bacteremia
Synonyms bacterial sepsis; bacteremia; Bacteremias; symptomatic bacteremia
Disease Class 1A70-1A7Z: Gonococcal infection
Definition An infectious disease caused by bacteria causing sepsis.
Disease Hierarchy
DIS5QJ9S: Bacterial infection
DIS6N9RZ: Bacteremia
ICD Code
ICD-11
ICD-11: 1A73
ICD-10
ICD-10: A54.4, A54.8
Disease Identifiers
MONDO ID
MONDO_0005229
MESH ID
D016470
UMLS CUI
C0004610
MedGen ID
482
HPO ID
HP:0031864
SNOMED CT ID
5758002

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 32 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Amikacin DM5PDRB Approved Small molecular drug [1]
Ampicillin DMHWE7P Approved Small molecular drug [2]
Azlocillin DMIR5QP Approved Small molecular drug [3]
Cefalotin DMVYSLE Approved Small molecular drug [4]
Cefamandole DMNEXZF Approved Small molecular drug [5]
Cefazolin DMPDYFR Approved Small molecular drug [6]
Cefonicid DMTX2BH Approved Small molecular drug [7]
Cefotaxime DMEB837 Approved NA [8]
Cefotetan DM07TX3 Approved Small molecular drug [9]
Cefoxitin DMY8NC4 Approved NA [10]
Ceftazidime DM41GRA Approved Small molecular drug [11]
Ceftizoxime DM3VOGS Approved Small molecular drug [12]
Ceftriaxone DMCEW64 Approved Small molecular drug [13]
Cefuroxime DMSIMD8 Approved Small molecular drug [14]
Cephapirin DMV2JNY Approved Small molecular drug [15]
Cilastatin DME2H5T Approved Small molecular drug [16]
Clavulanate DM2FGRT Approved Small molecular drug [17]
Clindamycin DM15HL8 Approved Small molecular drug [18]
Erythromycin DM4K7GQ Approved Small molecular drug [19]
Fusidic Acid DMWVCF3 Approved Small molecular drug [20]
Gentamicin DMKINJO Approved Small molecular drug [21]
Imipenem DMI9FBP Approved Small molecular drug [16]
Kanamycin DM2DMPO Approved Small molecular drug [22]
Linezolid DMGFPU2 Approved Small molecular drug [23]
Meticillin DMIKHN0 Approved Small molecular drug [24]
Metronidazole DMTIVEN Approved Small molecular drug [25]
Mezlocillin DMY5JEP Approved Small molecular drug [26]
Piperacillin DMTBKF3 Approved Small molecular drug [27]
Polymyxin B Sulfate DMN0LP8 Approved Small molecular drug [28]
Ticarcillin DM4ME02 Approved Small molecular drug [29]
Tobramycin DMUI0CH Approved Small molecular drug [30]
Vancomycin DM3JFIH Approved NA [31]
------------------------------------------------------------------------------------
⏷ Show the Full List of 32 Drug(s)
This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Exebacase DMXRCL2 Phase 3 Recombinant protein [32]
SAL-200 DMIWL5P Phase 2 NA [34]
HLF 1-11 DMDFG1O Phase 1/2 Peptide [35]
DSTA-4637S DMHC09K Phase 1 Antibody drug conjugate [36]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Drugs in Phase 2 Trial
Drug Name Drug ID Highest Status Drug Type REF
Heparin DM4ZP3W Phase 2/3 Trial Small molecular drug [33]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 19 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CPB2 TTP18AY Limited Biomarker [37]
PLAT TTXAGYU Limited Therapeutic [38]
TIRAP TTKU0LS Limited Biomarker [39]
ITGAM TTB69FJ moderate Altered Expression [40]
NOD2 TTYPUHA moderate Biomarker [41]
ADAMTS13 TTUREBK Strong Altered Expression [42]
CD248 TTYJWT7 Strong Biomarker [43]
CPE TTXPWO6 Strong Biomarker [44]
GALNS TTT9YPO Strong Biomarker [45]
GAST TT4LRVO Strong Biomarker [45]
GPR182 TTT23CG Strong Biomarker [46]
GRHL2 TTUGH4C Strong Altered Expression [47]
LNPEP TTY2KP7 Strong Genetic Variation [48]
SLC25A1 TTTD730 Strong Biomarker [49]
CS TTZA6B3 Definitive Genetic Variation [50]
DAPK3 TTERVQN Definitive Biomarker [51]
F12 TTRJSMV Definitive Biomarker [52]
IRAK4 TTILUKB Definitive Biomarker [53]
LCT TTA0OSE Definitive Biomarker [54]
------------------------------------------------------------------------------------
⏷ Show the Full List of 19 DTT(s)
This Disease Is Related to 55 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
PGLYRP4 OTI115BR Limited Biomarker [55]
GLRX5 OTE3L48D moderate Biomarker [56]
AMBP OTLU8GU8 Strong Genetic Variation [57]
APBB3 OTNUTR0N Strong Genetic Variation [58]
CAP1 OTYM8A2N Strong Genetic Variation [48]
CISH OT8T5NYL Strong Genetic Variation [59]
EDN3 OTN7Q9BE Strong Genetic Variation [60]
EMP1 OTSZHUHQ Strong Biomarker [61]
FOXD3 OTXYV6GO Strong Biomarker [62]
HACD1 OTEC7EP7 Strong Genetic Variation [48]
KCNMB1 OTO4KNJ4 Strong Biomarker [63]
MRTFA OTCVXASM Strong Genetic Variation [64]
OCLN OTSUTVWL Strong Altered Expression [65]
PAGR1 OTXR5PQ8 Strong Biomarker [45]
PGLYRP2 OTF8319A Strong Biomarker [66]
PIP OTH719AH Strong Biomarker [67]
PTPRG OT9N2WOF Strong Genetic Variation [68]
SAG OTDNS3ZQ Strong Genetic Variation [69]
SERPINB6 OT7G55IK Strong Genetic Variation [48]
SFTPA2 OT6SFOMU Strong Genetic Variation [70]
SORBS1 OTWH8762 Strong Genetic Variation [48]
SUMF2 OT37I8JL Strong Biomarker [71]
TFF2 OTRXB19X Strong Biomarker [72]
ASAP2 OTGEXULW Definitive Biomarker [73]
BRAP OTB7BAFQ Definitive Biomarker [74]
CDON OT81X593 Definitive Biomarker [51]
CSH1 OT33HTRR Definitive Genetic Variation [75]
CSH2 OTW8JVAN Definitive Genetic Variation [75]
DEFB103B OT8RWY64 Definitive Genetic Variation [76]
DEFB104A OTLQZR6K Definitive Biomarker [76]
ERCC8 OT0T4WKI Definitive Genetic Variation [75]
GPSM1 OTA0SJBG Definitive Genetic Variation [77]
HLA-DRA OT7KZMP2 Definitive Altered Expression [78]
IARS1 OT9WXH5N Definitive Biomarker [79]
IL12RB1 OTM1IJO2 Definitive Genetic Variation [80]
IMP4 OTYF1USY Definitive Biomarker [81]
IMPA1 OTBUVW1Z Definitive Biomarker [74]
IPO4 OT2N5020 Definitive Biomarker [81]
MARCHF2 OTADQ0OA Definitive Biomarker [82]
MAVS OTTQ0J64 Definitive Biomarker [83]
MRPS30 OTDXIAGG Definitive Biomarker [73]
MTPAP OT6HQ02S Definitive Biomarker [73]
NFKBIE OTLAYEL9 Definitive Genetic Variation [84]
PAPOLA OTPHD65D Definitive Biomarker [73]
PDAP1 OTJSWMOD Definitive Biomarker [73]
PHB2 OTCAX3AW Definitive Genetic Variation [85]
PHF20 OTCBVH5P Definitive Biomarker [86]
RAB3IL1 OT18H5HD Definitive Altered Expression [87]
RNASEH2C OTJL9ZRN Definitive Genetic Variation [77]
SETD1A OTVVWRIC Definitive Biomarker [88]
SH3BP4 OTVIRKW7 Definitive Biomarker [89]
SIL1 OTDI85I5 Definitive Genetic Variation [85]
SPPL2B OTI1PHMP Definitive Biomarker [81]
SUFU OT0IRYG1 Definitive Genetic Variation [90]
TNMD OTHLVA9G Definitive Genetic Variation [91]
------------------------------------------------------------------------------------
⏷ Show the Full List of 55 DOT(s)

References

1 Amikacin FDA Label
2 Ampicillin FDA Label
3 Azlocillin FDA Label
4 [Serratia rubidaea bacteremia]. Med Mal Infect. 2007 May;37(5):287-9.
5 Cefamandole FDA Label
6 Cefazolin FDA Label
7 Cefonicid FDA Label
8 Cefotaxime FDA Label
9 Cefotetan FDA Label
10 Cefoxitin FDA Label
11 Ceftazidime FDA Label
12 Ceftizoxime FDA Label
13 Ceftriaxone FDA Label
14 Cefuroxime FDA Label
15 Cephapirin FDA Label
16 Cilastatin FDA Label
17 Clavulanate FDA Label
18 Clindamycin FDA Label
19 Erythromycin FDA Label
20 Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2009 May;53(5):2059-65.
21 Gentamicin FDA Label
22 Kanamycin FDA Label
23 Linezolid FDA Label
24 Post-COVID-19 Infection With Meticillin-Sensitive Staphylococcus aureus (MSSA) Bacteremia, Discitis/Osteomyelitis, and Diffuse Abscesses: A Case Report. Cureus. 2022 Jun 10;14(6):e25824.
25 Metronidazole FDA Label
26 Mezlocillin FDA Label
27 Piperacillin FDA Label
28 Polymyxin B Sulfate FDA Label
29 Ticarcillin FDA Label
30 Tobramycin FDA Label
31 Vancomycin FDA Label
32 ClinicalTrials.gov (NCT04160468) Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase (DISRUPT). U.S. National Institutes of Health.
33 Heparin FDA Label
34 ClinicalTrials.gov (NCT03089697) Phase IIa Clinical Study of N-Rephasin SAL200. U.S. National Institutes of Health.
35 ClinicalTrials.gov (NCT00509847) A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis (LIST). U.S. National Institutes of Health.
36 ClinicalTrials.gov (NCT03162250) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics. U.S. National Institutes of Health.
37 Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis.Clin Appl Thromb Hemost. 2007 Oct;13(4):362-8. doi: 10.1177/1076029607305580.
38 Severe acute myocardial infarction during a staphylococcal septicemia with meningoencephalitis. A possible contraindication to thrombolytic treatment.Intensive Care Med. 1992;18(4):247-9. doi: 10.1007/BF01709842.
39 A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis.Nat Genet. 2007 Apr;39(4):523-8. doi: 10.1038/ng1976. Epub 2007 Feb 25.
40 In vivo Lipopolysaccharide Tolerance Recruits CD11b+ Macrophages to the Liver with Enhanced Bactericidal Activity and Low Tumor Necrosis Factor-Releasing Capability, Resulting in Drastic Resistance to Lethal Septicemia.J Innate Immun. 2017;9(5):493-510. doi: 10.1159/000475931. Epub 2017 Jul 5.
41 Importance of NOD2/CARD15 gene variants for susceptibility to and outcome of sepsis in Turkish children.Pediatr Crit Care Med. 2012 Mar;13(2):e73-7. doi: 10.1097/PCC.0b013e3182191c2e.
42 Von Willebrand factor and ADAMTS13 impact on the outcome of Staphylococcus aureus sepsis.J Thromb Haemost. 2020 Mar;18(3):722-731. doi: 10.1111/jth.14686. Epub 2019 Dec 22.
43 Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections.Antimicrob Agents Chemother. 2009 Jul;53(7):2846-51. doi: 10.1128/AAC.00247-09. Epub 2009 Apr 20.
44 External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance.Int J Antimicrob Agents. 2019 Oct;54(4):442-448. doi: 10.1016/j.ijantimicag.2019.07.017. Epub 2019 Aug 1.
45 Impact of contusion injury on intramuscular emm1 group a streptococcus infection and lymphatic spread.Virulence. 2018;9(1):1074-1084. doi: 10.1080/21505594.2018.1482180.
46 Changing Antimicrobial Resistance Trends in Kathmandu, Nepal: A 23-Year Retrospective Analysis of Bacteraemia.Front Med (Lausanne). 2018 Sep 19;5:262. doi: 10.3389/fmed.2018.00262. eCollection 2018.
47 Porphyromonas gingivalis Impairs Oral Epithelial Barrier through Targeting GRHL2.J Dent Res. 2019 Sep;98(10):1150-1158. doi: 10.1177/0022034519865184. Epub 2019 Jul 24.
48 The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis.Ann Clin Microbiol Antimicrob. 2017 Apr 5;16(1):24. doi: 10.1186/s12941-017-0199-8.
49 Treatment outcomes in patients with pyogenic vertebral osteomyelitis who have cirrhosis.Sci Rep. 2019 Oct 23;9(1):15223. doi: 10.1038/s41598-019-51758-w.
50 Phylogenetic position of Bartonella vinsonii subsp. arupensis based on 16S rDNA and gltA gene sequences.Int J Syst Evol Microbiol. 2001 Jan;51(Pt 1):179-182. doi: 10.1099/00207713-51-1-179.
51 Complex host genetic susceptibility to Staphylococcus aureus infections.Trends Microbiol. 2015 Sep;23(9):529-36. doi: 10.1016/j.tim.2015.05.008. Epub 2015 Jun 22.
52 CpaA Is a Glycan-Specific Adamalysin-like Protease Secreted by Acinetobacter baumannii That Inactivates Coagulation Factor XII.mBio. 2018 Dec 18;9(6):e01606-18. doi: 10.1128/mBio.01606-18.
53 Deficiency of interleukin-1 receptor-associated kinase 4 presenting as fatal Pseudomonas aeruginosa bacteremia in two siblings.Pediatr Infect Dis J. 2015 Mar;34(3):299-300. doi: 10.1097/INF.0000000000000550.
54 Impact of Staphylococcus aureus regulatory mutations that modulate biofilm formation in the USA300 strain LAC on virulence in a murine bacteremia model.Virulence. 2017 Nov 17;8(8):1776-1790. doi: 10.1080/21505594.2017.1373926. Epub 2017 Oct 4.
55 Peptidoglycan Recognition Protein 4 Limits Bacterial Clearance and Inflammation in Lungs by Control of the Gut Microbiota.Front Immunol. 2019 Sep 20;10:2106. doi: 10.3389/fimmu.2019.02106. eCollection 2019.
56 Trends in incidence and resistance patterns of Staphylococcus aureus bacteremia().Infect Dis (Lond). 2018 Jan;50(1):52-58. doi: 10.1080/23744235.2017.1405276. Epub 2017 Nov 21.
57 Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.Int J Antimicrob Agents. 2019 Apr;53(4):408-415. doi: 10.1016/j.ijantimicag.2018.11.001. Epub 2018 Nov 8.
58 A Core Genome Multilocus Sequence Typing Scheme for Enterococcus faecalis.J Clin Microbiol. 2019 Feb 27;57(3):e01686-18. doi: 10.1128/JCM.01686-18. Print 2019 Mar.
59 CISH and susceptibility to infectious diseases.N Engl J Med. 2010 Jun 3;362(22):2092-101. doi: 10.1056/NEJMoa0905606. Epub 2010 May 19.
60 Association of endothelin genetic variants and hospitalized infection complications in end-stage renal disease (ESRD) patients.BMC Nephrol. 2019 Jun 5;20(1):203. doi: 10.1186/s12882-019-1349-3.
61 Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. -lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis.Open Forum Infect Dis. 2019 Aug 14;6(10):ofz364. doi: 10.1093/ofid/ofz364. Online ahead of print.
62 Next-generation sequencing diagnostics of bacteremia in sepsis (Next GeneSiS-Trial): Study protocol of a prospective, observational, noninterventional, multicenter, clinical trial.Medicine (Baltimore). 2018 Feb;97(6):e9868. doi: 10.1097/MD.0000000000009868.
63 Group A Streptococcus Induces LAPosomes via SLO/1 Integrin/NOX2/ROS Pathway in Endothelial Cells That Are Ineffective in Bacterial Killing and Suppress Xenophagy.mBio. 2019 Oct 1;10(5):e02148-19. doi: 10.1128/mBio.02148-19.
64 Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections.J Antimicrob Chemother. 2019 Jul 1;74(7):1940-1944. doi: 10.1093/jac/dkz133.
65 Colonization of preterm gnotobiotic piglets with probiotic Lactobacillus rhamnosus GG and its interference with Salmonella Typhimurium.Clin Exp Immunol. 2019 Mar;195(3):381-394. doi: 10.1111/cei.13236. Epub 2018 Dec 2.
66 Peptidoglycan Recognition Protein 2 Regulates Neutrophil Recruitment Into the Lungs After Streptococcus pneumoniae Infection.Front Microbiol. 2019 Feb 19;10:199. doi: 10.3389/fmicb.2019.00199. eCollection 2019.
67 Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.Clin Infect Dis. 2019 Nov 27;69(12):2045-2056. doi: 10.1093/cid/ciz181.
68 Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children.Am J Hum Genet. 2016 Jun 2;98(6):1092-1100. doi: 10.1016/j.ajhg.2016.03.025. Epub 2016 May 26.
69 Lack of correlation of virulence gene profiles of Staphylococcus aureus bacteremia isolates with mortality.Microb Pathog. 2019 Aug;133:103543. doi: 10.1016/j.micpath.2019.103543. Epub 2019 May 15.
70 Genotypes, intrafamilial transmission, and virulence potential of nasal methicillin-resistant Staphylococcus aureus from children in the community.J Infect Chemother. 2009 Apr;15(2):84-91. doi: 10.1007/s10156-009-0668-x. Epub 2009 Apr 25.
71 Molecular epidemiology of Pseudomonas aeruginosa isolated from infected ICU patients: a French multicenter 2012-2013 study.Eur J Clin Microbiol Infect Dis. 2019 May;38(5):921-926. doi: 10.1007/s10096-019-03519-w. Epub 2019 Mar 2.
72 Loss of Trefoil Factor 2 Sensitizes Rat Pups to Systemic Infection with the Neonatal Pathogen Escherichia coli K1.Infect Immun. 2019 Apr 23;87(5):e00878-18. doi: 10.1128/IAI.00878-18. Print 2019 Mar.
73 In vivo-generated thrombin and plasmin do not activate the complement system in baboons.Blood. 2017 Dec 14;130(24):2678-2681. doi: 10.1182/blood-2017-06-788216. Epub 2017 Oct 11.
74 Molecular and epidemiological characterization of IMP-type metallo--lactamase-producing Enterobacter cloacae in a Large tertiary care hospital in Japan.Antimicrob Agents Chemother. 2014 Jun;58(6):3441-50. doi: 10.1128/AAC.02652-13. Epub 2014 Apr 7.
75 Potential synergy activity of the novel ceragenin, CSA-13, against carbapenem-resistant Acinetobacter baumannii strains isolated from bacteremia patients.Biomed Res Int. 2014;2014:710273. doi: 10.1155/2014/710273. Epub 2014 Mar 24.
76 Genetic variability in beta-defensins is not associated with susceptibility to Staphylococcus aureus bacteremia.PLoS One. 2012;7(2):e32315. doi: 10.1371/journal.pone.0032315. Epub 2012 Feb 22.
77 Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors.Infection. 2012 Feb;40(1):19-26. doi: 10.1007/s15010-011-0187-4. Epub 2011 Sep 2.
78 Expression of HLA-DRA and CD74 mRNA in whole blood during the course of complicated and uncomplicated Staphylococcus aureus bacteremia.Microbiol Immunol. 2017 Oct;61(10):442-451. doi: 10.1111/1348-0421.12533.
79 Molecular investigation of two clusters of hospital-acquired bacteraemia caused by multi-resistant Klebsiella pneumoniae using pulsed-field gel electrophoresis and in frequent restriction site PCR. Infection Control Group.J Hosp Infect. 2000 Oct;46(2):110-7. doi: 10.1053/jhin.2000.0815.
80 Interleukin-12 receptor beta1 deficiency presenting as recurrent Salmonella infection.Clin Infect Dis. 2003 Jul 1;37(1):137-40. doi: 10.1086/375229. Epub 2003 Jun 24.
81 First reported nosocomial outbreak of Serratia marcescens harboring bla (IMP-4) and bla (VIM-2) in a neonatal intensive care unit in Cairo, Egypt.Infect Drug Resist. 2018 Nov 8;11:2211-2217. doi: 10.2147/IDR.S174869. eCollection 2018.
82 Serratia marcescens Bacteremia: Nosocomial Cluster Following Narcotic Diversion.Infect Control Hosp Epidemiol. 2017 Sep;38(9):1027-1031. doi: 10.1017/ice.2017.137. Epub 2017 Jul 6.
83 Heterogeneous vancomycin-intermediate susceptibility in a community-associated methicillin-resistant Staphylococcus aureus epidemic clone, in a case of Infective Endocarditis in Argentina.Ann Clin Microbiol Antimicrob. 2011 Apr 28;10:15. doi: 10.1186/1476-0711-10-15.
84 Genetic Variation in NFKBIE Is Associated With Increased Risk of Pneumococcal Meningitis in Children.EBioMedicine. 2015 Dec 2;3:93-99. doi: 10.1016/j.ebiom.2015.11.048. eCollection 2016 Jan.
85 Number of positive blood cultures, biofilm formation, and adhesin genes in differentiating true coagulase-negative staphylococci bacteremia from contamination.Eur J Clin Microbiol Infect Dis. 2016 Jan;35(1):57-66. doi: 10.1007/s10096-015-2506-7.
86 Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible.Open Forum Infect Dis. 2018 Nov 19;5(12):ofy300. doi: 10.1093/ofid/ofy300. eCollection 2018 Dec.
87 Low antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe invasive disease.J Infect Dis. 2004 Mar 1;189(5):797-804. doi: 10.1086/381982. Epub 2004 Feb 18.
88 Prevalence of enterotoxins among Escherichia coli isolates causing bacteraemia.FEMS Microbiol Lett. 2010 May;306(2):117-21. doi: 10.1111/j.1574-6968.2010.01945.x.
89 Utility of a blood culture time to positivity-incorporated scoring model in predicting vascular infections in adults with nontyphoid Salmonella bacteremia.J Microbiol Immunol Infect. 2018 Oct;51(5):652-658. doi: 10.1016/j.jmii.2018.01.004. Epub 2018 Feb 21.
90 Polymorphisms in the SUFU gene are associated with organ injury protection and sepsis severity in patients with Enterobacteriacea bacteremia.Infect Genet Evol. 2013 Jun;16:386-91. doi: 10.1016/j.meegid.2013.03.025. Epub 2013 Mar 26.
91 Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin.Clin Infect Dis. 2004 Jan 15;38(2):243-51. doi: 10.1086/380645. Epub 2003 Dec 19.